INHIBITION OF PCSK9 AFFECTS SERUM LIPOPROTEIN FUNCTIONS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

被引：0
|
作者：
Palumbo, M. [1 ]
Adorni, M. P. [2 ]
Zimetti, F. [1 ]
Pavanello, C. [3 ]
Giammanco, A. [4 ]
Cefalu, A. B. [4 ]
Noto, D. [4 ]
Piro, S. [5 ]
Di Pino, A. [5 ]
Averna, M. [4 ]
Calabresi, L. [3 ]
Bernini, F. [1 ]
Purrello, F. [5 ]
Scicali, R. [5 ]
机构：
[1] Univ Parma, Dept Food & Drug, Parma, Italy
[2] Univ Parma, Dept Med & Surg, Unit Neurosci, Parma, Italy
[3] Univ Milan, Pharmacol & Biomol Sci, Milan, Italy
[4] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy
[5] ARNAS GARIBALDI NESIMA, Dept Med, Catania, Italy
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP222
引用
收藏
页码：E157 / E157
页数：1
相关论文
共 50 条
  • [21] Getting Real With PCSK9 Inhibitors in Familial Hypercholesterolemia
    Baass, Alexis
    Hegele, Robert A.
    CANADIAN JOURNAL OF CARDIOLOGY, 2018, 34 (08) : 959 - 961
  • [22] Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation?
    Silvino, J. P. P. .
    Carvalho, M. G.
    Reis, E. A.
    Mota, A. P. L.
    Gomes, K. B.
    Duarte, R. C. F.
    Guimaraes, M. C. J.
    Sousa, M. C. R.
    Azevedo, P. S.
    Silva, I. F. O.
    THROMBOSIS RESEARCH, 2021, 200 : 156 - 163
  • [23] STATINS, BUT NOT PCSK9 INHIBITORS, REDUCE THE ADIPOKINE CHEMERIN IN FAMILIAL HYPERCHOLESTEROLEMIA: FOCUS ON LIPOPROTEIN SUBFRACTIONS
    Tan, Lunbo
    Wang, Na
    Van der Zee, Leonie Van Vark
    Van Lennep, Jeanine Roeters
    Mulder, Monique T.
    Lu, Xifeng
    Danser, A. H. Jan
    Verdonk, Koen
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL) : E299 - E300
  • [24] STATINS, BUT NOT PCSK9 INHIBITORS, REDUCE THE ADIPOKINE CHEMERIN IN FAMILIAL HYPERCHOLESTEROLEMIA: FOCUS ON LIPOPROTEIN SUBFRACTIONS
    Tan, L.
    Wang, N.
    Van Vark-Van der Zee, L.
    Van Lennep, J. Roeters
    Mulder, M.
    Lu, X.
    Danser, A. H.
    Verdonk, K.
    ATHEROSCLEROSIS, 2023, 379 : S173 - S173
  • [25] Lipoprotein (a), arterial inflammation, and PCSK9 inhibition
    Tardif, Jean-Claude
    Rheaume, Eric
    Rhainds, David
    Dube, Marie-Pierre
    EUROPEAN HEART JOURNAL, 2019, 40 (33) : 2782 - 2784
  • [26] Lipoprotein(a) and PCSK9 inhibition: clinical evidence
    Ruscica, Massimiliano
    Greco, Maria Francesca
    Ferri, Nicola
    Corsini, Alberto
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0L) : L53 - L56
  • [27] The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
    Meshkov, Alexey
    Ershova, Alexandra
    Kiseleva, Anna
    Zotova, Evgenia
    Sotnikova, Evgeniia
    Petukhova, Anna
    Zharikova, Anastasia
    Malyshev, Pavel
    Rozhkova, Tatyana
    Blokhina, Anastasia
    Limonova, Alena
    Ramensky, Vasily
    Divashuk, Mikhail
    Khasanova, Zukhra
    Bukaeva, Anna
    Kurilova, Olga
    Skirko, Olga
    Pokrovskaya, Maria
    Mikova, Valeriya
    Snigir, Ekaterina
    Akinshina, Alexsandra
    Mitrofanov, Sergey
    Kashtanova, Daria
    Makarov, Valentin
    Kukharchuk, Valeriy
    Boytsov, Sergey
    Yudin, Sergey
    Drapkina, Oxana
    GENES, 2021, 12 (01) : 1 - 17
  • [28] PCSK9 inhibition in children with familial hypercholesterolaemia
    Hegele, Robert A.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (10): : 686 - 688
  • [29] Inhibition of PCSK9 as a Novel Strategy for the Treatment of Hypercholesterolemia
    Lopez, Dayami
    DRUG NEWS & PERSPECTIVES, 2008, 21 (06) : 323 - 330
  • [30] PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia
    Reeskamp, Laurens F.
    Tromp, Tycho R.
    Hovingh, G. Kees
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (03) : 270 - 271
12345